Intrasense SA

Intrasense SA

EEURONEXT:ALINS
0.21
EUR
+0.00
(+1.44%)
12.17MMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
1.25
0.55
0.45
0.29
0.18
0.16
0.16
0.15
0.15
0.12
0.06
0.04
0.06
- -
Basic EPS, GAAP
-0.55
-1.25
-0.43
-0.17
-0.17
-0.08
-0.04
-0.03
-0.04
-0.11
-0.07
-0.1
-0.21
- -
Free Cash Flow per Basic Share
-0.87
- -
- -
- -
- -
- -
- -
-0.04
-0.05
-0.11
-0.1
-0.11
- -
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
0.82
0.45
0.19
0.17
0.05
0.07
0.03
0.09
0.16
0.06
0.14
0.08
-0.12
0.08
Tangible Book Value per Share
0.3
0.09
-0.01
0.06
-0.04
0.02
-0.02
0.04
0.12
-0.01
0.08
-0.05
-0.22
-0.05
Basic Weighted Avg Shares
3
4
6
11
12
19
20
23
28
31
51
53
53
52
Sales/Revenue/Turnover
4
2
3
3
2
3
3
3
4
4
3
2
3
- -
Operating Margin (%)
-62.46
-216.39
-75.86
-58.49
-82.36
-27.73
-19.86
-15.08
-27.52
-89
-106.11
-222.18
-202.03
- -
Depreciation Expense
1
2
1
1
1
1
- -
1
1
1
1
1
2
- -
Net Income, GAAP
-2
-5
-3
-2
-2
-2
-1
-1
-1
-3
-4
-5
-11
- -
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
-44.24
-227.01
-95.14
-58.56
-94.63
-49.19
-27.49
-20.46
-28.74
-90.24
-108.26
-220.68
-360.94
- -
Working Capital
4
3
3
2
1
2
- -
2
5
1
5
1
1
1
LT Debt
1
2
2
1
1
- -
2
2
1
1
1
3
9
3
Total Equity
4
2
1
2
1
1
1
2
5
2
7
4
-6
4
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
-40.9
-197.73
-174.36
-119.02
-177.05
-145.48
-89.94
-51.63
-33.7
-97.73
-76.97
-90.57
- -
- -

Capital Structure

EUR

•

in mil. unless spec.
Dec'23
Jun'24
Dec'24
ST Debt
- -
- -
1
LT Borrowings
1
1
1
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
52
52
53
Market Capitalization
19
14
12

Working Capital

EUR

•

in mil. unless spec.
Dec'23
Jun'24
Dec'24
Total Current Assets
6
4
2
Cash, Cash Equivalents & STI
5
1
1
Accounts Receivable, Net
1
1
- -
Inventories
- -
- -
- -
Total Current Liabilities
2
2
2
Payables & Accruals
- -
- -
- -
ST Debt
- -
- -
1
Deferred Revenue
- -
- -
- -

Growth Rates

EUR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
36.1%
6.36%
-258.36%
Free Cash Flow
- -
- -
- -
Net Income, GAAP
30.63%
82.73%
110.01%
Sales/Revenue/Turnover
2.62%
-0.33%
28.4%
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

EUR

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
3
2024
- -
- -
2
2025
- -
- -
3

Semi-annual Earnings Per Share

EUR

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
-0.07
2024
- -
- -
-0.1
2025
- -
- -
-0.21

Semi-annual Dividends Per Share

EUR

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
- -
2024
- -
- -
- -
2025
- -
- -
- -

Company Description

CEO
Stephen Armand
Full Time Employees
58
Sector
Technology services
Industry
Packaged software
Address
1231, avenue du Mondial 98 Montpellier OCC France 34000
IPO Date
Feb 22, 2012
Business
Intrasense S.A. develops and markets AI-enhanced medical imaging software solutions that facilitate diagnosis, decision-making, and therapeutic follow-up for healthcare professionals worldwide; its core offerings include the Myrian platform, a multimodal advanced visualization tool with clinical applications and artificial intelligence algorithms for pathologies such as prostate, lung, brain, liver lesions, pancreatic cancer, and bone lesions; the Lifow platform, an oncology-focused solution that automates lesion identification and measurement to support multidisciplinary patient care; and related services encompassing software installation, maintenance, rental, and support. Founded in 2004 and headquartered in Montpellier, France, the company operates in over 40 countries with approximately 1,200 customers and maintains a presence including offices in Europe, the United States, Germany, and China. As a subsidiary of Guerbet Group following the 2023 acquisition of a majority stake through a capital increase and tender offer, Intrasense benefits from strategic synergies including a licensing agreement integrating Guerbet's AI algorithms into its platforms; recent developments encompass CE marking under MDR for Myrian 2.14 in 2025, a new strategic roadmap emphasizing innovation, product expansion, and geographic growth, alongside H1 2025 revenue growth of 33% to €1.6 million driven by European sales.